Austin, United States, July 07, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Transthyretin Amyloidosis Treatment Market was valued at USD 8.95 Billion in 2025 and is projected to reach USD 35.10 Billion by 2035, registering a CAGR of 14.64% during 2026–2035. Growth is supported by increasing diagnosis of ATTR cardiomyopathy (ATTR-CM), expanding use of gene-silencing therapies and TTR stabilizers, favorable regulatory approvals, and rising investment in rare disease therapeutics.
The transthyretin amyloidosis treatment market has been transformed by gene-silencing drugs like patisiran and vutrisiran that stop the liver from producing the misfolded transthyretin protein, alongside TTR stabilizers preventing misfolding through a different mechanism. In November 2024, the FDA approved Alnylam's vutrisiran as a subcutaneous RNAi therapy for ATTR cardiomyopathy, meaningfully expanding an already-approved polyneuropathy drug. Better diagnostic tools, especially nuclear cardiac imaging identifying ATTR-CM without biopsy, are driving far more patients into diagnosis and treatment than was possible a decade ago globally.